Biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor-associated DNA , both in Circulating Tumor Cells and in plasma (cell-free circulating tumor DNA). The Company's mission is to improve outcomes for cancer patients by advancing oncology diagnostics. Biocept utilizes patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. Additionally, the Company offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. Biocept's strategic focus is to promote its unique technology (CEE, cell enrichment and extraction) and family of laboratory tests (OncoCEE) to the Oncology Community. 

The CEE system has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. Examples of these rare cells are circulating tumor cells in patients with early-stage, metastatic or recurrent cancers. Biocept provides products and services to detect and analyze these rare cells in order to provide information that physicians can use to make treatment decisions. The Company employs its unique laboratory tests through an offering of services to medical/surgical oncologists, pathologists, hospitals, cancer centers, universities, and pharmaceutical/clinical researchers.

Show more
TypePublic
HQSan Diego, US
Founded1993
Size (employees)42 (est)
Websitebiocept.com
Biocept was founded in 1993 and is headquartered in San Diego, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Biocept

Michael W. Wallace

Michael W. Wallace

President & CEO
Lyle Arnold

Lyle Arnold

Svp & CSO
Show more

Biocept Office Locations

Biocept has an office in San Diego
San Diego, US (HQ)
5810 Nancy Ridge Dr
Show all (1)
Report incorrect company information

Biocept Financials and Metrics

Biocept Revenue

Biocept's revenue was reported to be $5.07 m in FY, 2017
USD

Revenue (Q2, 2018)

1.6 m

Gross profit (Q2, 2018)

(3.5 m)

Gross profit margin (Q2, 2018), %

(215.2%)

EBIT (Q2, 2018)

(12.3 m)

Market capitalization (19-Sep-2018)

7.3 m

Closing stock price (19-Sep-2018)

3.2

Cash (30-Jun-2018)

2.6 m
Biocept's current market capitalization is $7.3 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

5.1 m

Cost of goods sold

9.3 m

Gross profit

(4.3 m)

Gross profit Margin, %

(84%)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

76.8 k164.9 k221.4 k662.9 k1 m1.7 m1.3 m806.9 k1.6 m

Cost of goods sold

985.2 k1.2 m1.5 m1.7 m1.9 m2.1 m2.4 m2.4 m5.1 m

Gross profit

(908.5 k)(994.9 k)(1.3 m)(1 m)(829 k)(446.4 k)(1.1 m)(1.6 m)(3.5 m)

Gross profit Margin, %

(1183%)(603%)(566%)(152%)(79%)(27%)(85%)(202%)(215%)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

5.4 m8.8 m4.6 m2.1 m

Accounts Receivable

10.6 k34.2 k129 k1.2 m

Inventories

338.7 k435.9 k484.6 k498.7 k

Current Assets

5.9 m9.6 m5.8 m4.3 m
Quarterly
USDQ3, 2017Q1, 2018Q2, 2018

Cash

9.3 m2.6 m

Accounts Receivable

1.3 m1.4 m

Inventories

412.9 k491 k537 k

Current Assets

11.8 m5.4 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(15.9 m)(16.9 m)(18.4 m)(21.6 m)

Depreciation and Amortization

251.2 k261.4 k322 k575.7 k

Inventories

(401.4 k)(80.4 k)494.7 k100.9 k

Accounts Payable

(981.9 k)(51.8 k)332.7 k349.9 k
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Inventories

412.9 k

Accounts Payable

970.5 k612.5 k766.4 k853.3 k946.3 k1.7 m1.4 m1.8 m1.6 m
USDY, 2018

Financial Leverage

3.3 x
Show all financial metrics
Report incorrect company information

Biocept Online and Social Media Presence

Embed Graph
Report incorrect company information

Biocept News and Updates

Biocept Names Edwin C. Hendrick as Senior Vice President, Chief Commercial Officer

SAN DIEGO, Sept. 10, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the appointment of Edwin...

Highmark Health's VITAL Innovation Program testing benefits of Biocept's liquid biopsy platform for improving outcomes and lowering costs of treatment for patients with non-small cell lung cancer

PITTSBURGH and SAN DIEGO, Aug. 23, 2018 /PRNewswire/ -- Highmark Health announced today that through its VITAL Innovation Program, it is testing Biocept, Inc.'s Target Selector™ liquid biopsy platform designed to help oncologists improve the diagnosis and treatment of patients with...

Biocept Reports Second Quarter 2018 Financial Results

SAN DIEGO, Aug. 14, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the three and six...

Biocept to Release Second Quarter 2018 Financial Results and Host Investor Conference Call on August 14, 2018

SAN DIEGO, Aug. 9, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release...

Biocept Announces $11.6 Million in Expected Gross Proceeds from Recently Expired Rights Offering

SAN DIEGO, Aug. 9, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announced today that the Company's previously...

Biocept Announces Agreement with Managed Care Plan to Study the Benefits of Implementing Liquid Biopsy to Improve Patient Outcomes and Lower Healthcare Costs

SAN DIEGO, Aug. 6, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered into an agreement with ...
Show more
Report incorrect company information

Biocept Company Life and Culture

Report incorrect company information